hPSMA-1-CAR

N/A

Report date: 2025/06/11 10:53:27

Base Information

Drug NamehPSMA-1-CAR
Drug Alias NamembIL12-engineered anti-PSMA CAR T-cell therapy (Eureka therapeutics/Beckman Research Institute)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionProstate-Specific Membrane Antigen modulatorsImmunostimulantsInterleukin-12 receptor stimulants +[4] 
TargetsProstate-Specific Membrane AntigenInterleukin-12 receptor
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesBeckman Research Institute
China Registration ClassN/A

Develop Information

Active CompaniesBeckman Research InstituteEureka Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A